Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Dapi. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.81 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.81 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.81 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.81 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.81 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.81 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.81 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.81 |
| ▸ | PRMT7 | Q9NVM4 | 1/20 | 0.81 |
| ▸ | F2 | P00734 | 2/20 | 0.61 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.53 |
| ▸ | F10 | P00742 | 1/20 | 0.52 |
| ▸ | PLG | P00747 | 1/20 | 0.52 |
| ▸ | PLAU | P00749 | 1/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dapi SCHEMBL30442885 | 1.00 | PRMT5 (0.81) | PRMT5PRMT3CARM1EHMT2PRMT6 | |
| Dapi SCHEMBL2464378 | 1.00 | PRMT5 (0.81) | PRMT5PRMT3CARM1EHMT2PRMT6 | |
| Dapi SCHEMBL15966967 | 0.98 | PRMT5 (0.79) | PRMT5PRMT3CARM1EHMT2PRMT6 | |
| Dapi SCHEMBL3492008 | 0.98 | PRMT5 (0.79) | PRMT5PRMT3CARM1EHMT2PRMT6 | |
| Dapi SCHEMBL29350295 | 0.98 | PRMT5 (0.83) | PRMT5PRMT3CARM1EHMT2PRMT6 | |
| Dapi SCHEMBL28176609 | 0.98 | PRMT5 (0.83) | PRMT5PRMT3CARM1EHMT2PRMT6 | |
| Dapi SCHEMBL235865 | 0.98 | PRMT5 (0.83) | PRMT5PRMT3CARM1EHMT2PRMT6 | |
| SCHEMBL29428907 | 0.97 | PRMT5 (0.81) | PRMT5PRMT3CARM1EHMT2PRMT6 | |
| SCHEMBL14854556 | 0.97 | PRMT5 (0.81) | PRMT5PRMT3CARM1EHMT2PRMT6 | |
| Dapi SCHEMBL1609032 | 0.95 | PRMT5 (0.79) | PRMT5PRMT3CARM1EHMT2PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1485 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120118971-A | Methods and compounds for modifying mitochondrial function | 小利兰·斯坦福大学托管委员会 | 2025-06-10 | — | — | CN | claimed |
| WO-2025005467-A1 | 3D PRINTING RESIN COMPOSITION FOR TRANSPARENT STRUCTURE, FLUORESCENT IMPLANT GUIDE, AND MANUFACTURING METHOD FOR COMPOSITION AND GUIDE | 정인선 | 2025-01-02 | — | — | WO | claimed |
| US-20240425692-A1 | 3D PRINTING RESIN COMPOSITION AND FLUORESCENT IMPLANT GUIDE FOR TRANSPARENT STRUCTURE, AND MANUFACTURING METHOD THEREOF | JEONG IN SUN (KR) | 2024-12-26 | — | — | US | claimed |
| CN-118956744-A | Method and kit for capturing fetal nucleated red blood cells | 北京安琪尔基因医学科技有限公司 | 2024-11-15 | — | — | CN | claimed |
| CN-116179190-A | Circularly polarized luminescent material and preparation method and application thereof | 中国科学院化学研究所 | 2023-05-30 | — | — | CN | claimed |
| CN-114929242-A | Methods and compounds for modifying mitochondrial function | 小利兰·斯坦福大学托管委员会 | 2022-08-19 | — | — | CN | claimed |
| EP-2802871-B1 | CHARACTERIZATION OF SUBVISIBLE PARTICLES USING A PARTICLE ANALYZER | TAKEDA PHARMACEUTICALS CO (JP) | 2022-07-27 | — | — | EP | claimed |
| CN-113024437-B | Preparation method of 4', 6-diamidino-2-phenylindole dihydrochloride | 苏州百灵威超精细材料有限公司 | 2022-05-06 | — | — | CN | claimed |
| CN-113024437-A | Preparation method of 4', 6-diamidino-2-phenylindole dihydrochloride | 苏州百灵威超精细材料有限公司 | 2021-06-25 | — | — | CN | claimed |
| US-20210190775-A1 | COMPOSITIONS AND METHODS FOR TAGGING AND DETECTING NUCLEIC ACIDS | NANOCO TECHNOLOGIES LTD. (GB) | 2021-06-24 | — | — | US | claimed |
| US-20170299482-A1 | COUNTERSTAINS FOR A BIOLOGICAL SAMPLE | DIAGNOSTIC BIOSYSTEMS (US) | 2017-10-19 | — | — | US | claimed |
| EP-2802871-A2 | CHARACTERIZATION OF SUBVISIBLE PARTICLES USING A PARTICLE ANALYZER | Baxter International Inc (US) | 2014-11-19 | — | — | EP | claimed |
| WO-2013106772-A2 | CHARACTERIZATION OF SUBVISIBLE PARTICLES USING A PARTICLE ANALYZER | BAXTER INTERNATIONAL, INC. (US) | 2013-07-18 | — | — | WO | claimed |
| EP-2470535-A2 | COMPOSITIONS, METHODS, AND KITS FOR DETERMINING AN ALKYL TRANSFERASE | Duke University (US) | 2012-07-04 | — | — | EP | claimed |
| WO-2011028507-A2 | COMPOSITIONS, METHODS, AND KITS FOR DETERMINING AN ALKYL TRANSFERASE | DUKE UNIVERSITY (US) | 2011-03-10 | — | — | WO | claimed |
| EP-1985311-A1 | AGENT FOR TARGETING DRUG TO CEREBRAL NEURON | Kagoshima University (JP) | 2008-10-29 | — | — | EP | claimed |
| EP-1854873-A2 | Microorganism detecting kit, microorganism counting apparatus, and microorganism counting process | Matsushita Ecology Systems Co., Ltd. (JP) | 2007-11-14 | — | — | EP | claimed |
| US-20040005365-A1 | Carcinostatic substance for compatible administration, process of administrating same and process of rapidly inspecting same | OGURO MASAO (JP) | 2004-01-08 | — | — | US | claimed |
| EP-0675924-B1 | CYCLIC-SUBSTITUTED UNSYMMETRICAL CYANINE DYES | MOLECULAR PROBES INC (US) | 2001-12-12 | — | — | EP | claimed |
| EP-0715854-A2 | Carcinostatic compositions containing cis-oxalato and one or more other compatible carcinostatic substances | Tanaka Kikinzoku Kogyo K.K. (JP) | 1996-06-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040005365-A1 | Carcinostatic substance for compatible administration, process of administrating same and process of rapidly inspecting same | FOLH1, CCKBR, PSPH | PRMT5 4062/4885PRMT3 3988/4885CARM1 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.